Literature DB >> 9309990

A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol.

S D Anderson1, J Brannan, J Spring, N Spalding, L T Rodwell, K Chan, I Gonda, A Walsh, A R Clark.   

Abstract

We developed a bronchial provocation test (BPT) with a dry powder preparation of mannitol. The mannitol was inhaled from gelatin capsules containing 5, 10, 20, or 40 mg to a cumulative dose of 635 mg, and was delivered via an inhalator, Halermatic, or Dinkihaler device. We studied the airway sensitivity to inhaled mannitol, the repeatability of the response, and the recovery after challenge in 43 asthmatic subjects 18 to 39 yr of age who had a 20% decrease in FEV1 in response to inhaling a 4.5% NaCl. We compared this with the airway response to methacholine in 25 subjects. The geometric mean (GM) for the dose of dry mannitol required to reduce the FEV1 by 15% of the baseline value (PD15) was 64 mg, with a 95% confidence interval (CI) of 45 to 91. Subjects responsive to mannitol had a PD20 to metacholine of < 7.8 mumol, with a GM of 0.7 mumol (CI: 0.4 to 1.2). For the first of two challenges to mannitol the PD15 was 59 mg (CI: 36 to 97) and for the second the PD15 was 58 mg (CI: 35 to 94) p = 0.91 (n = 23). Spontaneous recovery to within 5% of baseline occurred within 60 min and within 10 min after 0.5 mg terbutaline sulfate was inhaled. Arterial oxygen saturation (SaO2) remained at 93% or above during mannitol challenge. Subjects tolerated the inhalation of the mannitol well. A dry powder preparation of mannitol may be suitable to develop for bronchial provocation testing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9309990     DOI: 10.1164/ajrccm.156.3.9701113

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  50 in total

1.  Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation.

Authors:  C M Salome; J D Leuppi; R Freed; G B Marks
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139

Review 2.  Exercise-induced bronchospasm in the elite athlete.

Authors:  Kenneth W Rundell; David M Jenkinson
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

3.  Mid-expiratory flow versus FEV1 measurements in the diagnosis of exercise induced asthma in elite athletes.

Authors:  J W Dickinson; G P Whyte; A K McConnell; A M Nevill; M G Harries
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

Review 4.  Making the diagnosis of asthma in the athlete.

Authors:  Chris Randolph
Journal:  Clin Rev Allergy Immunol       Date:  2005-10       Impact factor: 8.667

Review 5.  Diagnostic and therapeutic value of airway challenges in asthma.

Authors:  Donald W Cockcroft; Beth E Davis
Journal:  Curr Allergy Asthma Rep       Date:  2009-05       Impact factor: 4.806

6.  Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols.

Authors:  N Y Chew; H K Chan
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 7.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

8.  Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases.

Authors:  Hui Xin Ong; Daniela Traini; Giulia Ballerin; Lucy Morgan; Lachlan Buddle; Santo Scalia; Paul M Young
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

9.  Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiers.

Authors:  Malcolm Sue-Chu; John D Brannan; Sandra D Anderson; Nora Chew; Leif Bjermer
Journal:  Br J Sports Med       Date:  2010-05-10       Impact factor: 13.800

10.  Use of mannitol inhalation challenge in assessment of cough.

Authors:  Sheldon Spector
Journal:  Lung       Date:  2009-09-16       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.